NZ220612A - 11 residue influenza virus peptide and vaccines - Google Patents

11 residue influenza virus peptide and vaccines

Info

Publication number
NZ220612A
NZ220612A NZ220612A NZ22061283A NZ220612A NZ 220612 A NZ220612 A NZ 220612A NZ 220612 A NZ220612 A NZ 220612A NZ 22061283 A NZ22061283 A NZ 22061283A NZ 220612 A NZ220612 A NZ 220612A
Authority
NZ
New Zealand
Prior art keywords
vaccines
residue
influenza virus
virus peptide
peptide
Prior art date
Application number
NZ220612A
Inventor
N Green
S Alexander
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of NZ220612A publication Critical patent/NZ220612A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
NZ220612A 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines NZ220612A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41045582A 1982-08-23 1982-08-23

Publications (1)

Publication Number Publication Date
NZ220612A true NZ220612A (en) 1988-07-28

Family

ID=23624803

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ205341A NZ205341A (en) 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines
NZ220612A NZ220612A (en) 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ205341A NZ205341A (en) 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines

Country Status (16)

Country Link
EP (1) EP0116629A4 (en)
JP (1) JPS59501714A (en)
KR (1) KR840006198A (en)
AU (1) AU570929B2 (en)
DK (1) DK203684A (en)
ES (1) ES8505819A1 (en)
FI (1) FI841583A (en)
GR (1) GR78931B (en)
IL (1) IL69556A (en)
IT (1) IT1168636B (en)
NO (1) NO161002C (en)
NZ (2) NZ205341A (en)
PH (1) PH18872A (en)
PT (1) PT77230B (en)
WO (1) WO1984000687A1 (en)
ZA (1) ZA836080B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR241713A1 (en) * 1984-08-30 1992-11-30 Smithkline Beckman Corp Vaccinal polypeptides
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
KR910700259A (en) * 1989-01-12 1991-03-14 리차드 이. 림바크 How T-cell Recognized Peptide Modifications Influence the Immune Response
EP0621339B1 (en) * 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
JP2996864B2 (en) * 1994-03-30 2000-01-11 寳酒造株式会社 Antibody variable region DNA
AU2007249160B2 (en) * 2006-05-15 2013-09-12 I2 Pharmaceuticals, Inc. Neutralizing antibodies to influenza viruses
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
CA2663388C (en) * 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
ITTO20070066A1 (en) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc ANTI-IDIOTYPE MONOCLONAL ANTIBODIES MIMOTOPI ANTIGENE GP 120 DI HIV
CA2680237C (en) 2007-03-27 2018-11-06 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
ITTO20080204A1 (en) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc MONOCLONAL ANTIBODIES ACTIONS TO REACT WITH A PLURALITY OF SUBTIPS OF THE INFLUENTIAL VIRUS A
AU2009228058A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
ITTO20080398A1 (en) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc MONOCLONAL ANTIBODIES HAVING PROPERTY OF HOSUBLICTIC CROSS-NEUTRALIZATION FOR INFLUENTIAL VIRUSES OF SUBTIPLE TYPE H1
ITTO20080964A1 (en) 2008-12-22 2010-06-23 Natimab Therapeutics S R L ANTI-HCV MONOCLONAL ANTIBODY AS A MEDICATION FOR THERAPEUTIC TREATMENT AND THE PREVENTION OF HCV INFECTIONS
US8975378B2 (en) 2008-12-25 2015-03-10 Osaka University Human anti-human influenza virus antibody
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
WO2010132604A2 (en) * 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
IT1395961B1 (en) * 2009-06-01 2012-11-02 Pomona Biotechnologies Llc MONOCLONAL ANTIBODIES AS A MEDICATION FOR THERAPEUTIC AND / OR PROFILACTIC TREATMENT OF INFLUENCIAL VIRUS INFECTIONS (H1N1) OF SWINE ORIGIN (S-OIV)
WO2011103453A2 (en) * 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
KR20130075732A (en) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 Influenza virus vaccines and uses thereof
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
EP4241785A3 (en) 2011-09-20 2023-09-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
WO2013096828A1 (en) 2011-12-22 2013-06-27 Sea Lane Biotechnologies, Llc Surrogate binding proteins
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63224A (en) * 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom

Also Published As

Publication number Publication date
NO841540L (en) 1984-04-17
FI841583A0 (en) 1984-04-19
NO161002C (en) 1989-06-21
PT77230A (en) 1983-09-01
PH18872A (en) 1985-10-21
ES525088A0 (en) 1985-06-16
DK203684D0 (en) 1984-04-18
PT77230B (en) 1986-02-04
NZ205341A (en) 1988-07-28
AU570929B2 (en) 1988-03-31
IL69556A (en) 1988-05-31
IL69556A0 (en) 1983-11-30
ZA836080B (en) 1984-04-25
KR840006198A (en) 1984-11-22
EP0116629A4 (en) 1987-06-29
ES8505819A1 (en) 1985-06-16
IT1168636B (en) 1987-05-20
NO161002B (en) 1989-03-13
AU1947183A (en) 1984-03-07
IT8348868A0 (en) 1983-08-22
GR78931B (en) 1984-10-02
FI841583A (en) 1984-04-19
EP0116629A1 (en) 1984-08-29
WO1984000687A1 (en) 1984-03-01
DK203684A (en) 1984-04-18
JPS59501714A (en) 1984-10-11

Similar Documents

Publication Publication Date Title
NZ205341A (en) 37 residue influenza virus peptide and vaccines
GB2181435B (en) Recombinant lav/htlv virus and vaccines
IL61904A (en) Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
JPS6425800A (en) T-cell epitope of hepatities b virus nucleocapside protein
HK38293A (en) Hepatitis c virus
EP0256878A3 (en) Vaccines
IL64847A (en) Immunomodulating phosphorylsubstituted muramylpeptide analogues and pharmaceutical compositions containing them
SG102092G (en) Hepatitis c virus
IL80895A0 (en) Material and methods for herpes simplex virus vaccination and diagnosis based on gd-2 glycoprotein
AU1255383A (en) Foot and mouth disease viral antigenic peptides
ZA835014B (en) Avian proventriculitis vaccine
EP0210931A3 (en) Vaccine against varicella-zoster virus
GB2130090B (en) Pharmaceutical preparations and compositions
NZ221374A (en) Recombinant interferon and compositions containing it
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
IL89118A0 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
HK79890A (en) Prophylactic and therapeutic use of muramyl peptides and their analogues against viral infections
IL79740A0 (en) Hepatitis vaccine
ZA866582B (en) Recombinant virus
ZA903142B (en) Canine corona virus vaccine
NZ220611A (en) 30 residue influenza virus peptide, vaccines and antibodies
GB2181434A (en) Hepatitis b virus vaccine and process for its preparation
GB8502096D0 (en) Influenza vaccine
ZA837058B (en) Peptide and use thereof
IL65920A (en) Anti-brucellosis vaccine and its preparation